Business Wire

ADVA

14.4.2022 09:02:06 CEST | Business Wire | Press release

Share
ADVA extends GNSS assurance software to protect third-party timing receivers from cyberattacks

ADVA (FSE: ADV) today extended its Ensemble Sync Director GNSS assurance software to integrate any third-party vendor’s GNSS receiver observables at scale. A key pillar of ADVA’s aPNT+ technology, Ensemble Sync Director is now vendor-agnostic, providing defense-in-depth, resilient and assured PNT for more customers than ever before. Ensemble Sync Director can now transparently show and analyze GNSS observables from third-party receivers in even the largest deployments. This is key as synchronization based on satellite signals is vulnerable to failure, interference and cyberthreats, and so network operators urgently need to protect their critical timing with continuous monitoring and assurance. Now, they have the power to remotely detect issues with GNSS receivers from any vendor, helping to maintain high-quality timing performance, avoid disruptions and reduce operating costs.

“The number of GNSS devices in use is growing by the day, with many networks now relying on hundreds or even thousands of receivers. At the same time, the risks to satellite-based timing have never been greater, including the rising threat of jamming and spoofing attacks. By extending our GNSS assurance application capabilities beyond our own timing equipment, we’re empowering many more customers to protect their mission-critical synchronization in new or deployed infrastructure,” said Gil Biran, GM of Oscilloquartz, ADVA. “Our Ensemble Sync Director, with comprehensive GNSS assurance for both resilient and assured PNT, provides a simple, scalable and highly cost-efficient way to harness our unique experience and expertise in managing a huge number of GNSS-dependent network elements.”

ADVA’s Oscilloquartz GNSS assurance solution for integrating third-party receiver data is an extension of its Sync Director application, part of the Ensemble Controller network management platform. It offers centralized in-service monitoring and analysis of GNSS status and reliability as well as AI/ML-based prediction and prevention of obstruction, jamming and spoofing. Using topology and timing chain mapping, Ensemble Sync Director displays the entire timing network infrastructure in a user-intuitive graphical format. ADVA’s GNSS assurance capabilities are aligned with the goals of the DHS Resilient PNT Conformance Framework and future IEEE P1952 Resilient PNT Standard to protect critical infrastructure. Available from ADVA Professional Services, the new solution is ideal for network operators in telecoms, power utilities, financial trading, data centers and more, who need to ensure robust, reliable and resilient GNSS timing. It also offers significant value to system integrator vendors looking to add vital GNSS protection capabilities to their synchronization portfolio.

“People are increasingly aware of the risk factors affecting GNSS-reliant systems, as well as the heavy price that disruption can bring. Whether they are addressing PNT regulations or responding to the precarious geopolitical situation, more and more network operators are looking to take urgent action to safeguard their timing architectures with resilient and assured PNT capabilities. That’s why we’re extending our GNSS assurance software with real-time monitoring to integrate third-party timing receiver data and enable more customers to proactively protect their critical infrastructure,” commented Michael Port, VP of product line management at ADVA. “Scalable and easy to implement, our new offering adds instant value. What’s more, Ensemble Sync Director supports open integration, enabling end-to-end vendor-agnostic sync and timing network management.”

Further information is available in these slides: https://adva.li/third-party-gnss-assurance-slides .


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye